New article - What's Next For $GBSN http://fina
Post# of 107664
(Total Views: 152)
Posted On: 04/07/2017 8:53:31 AM
New article - What's Next For $GBSN
http://finance.yahoo.com/news/great-basin-wha...00433.html
NEW YORK, NY / ACCESSWIRE / April 7, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is issuing a comprehensive report with no obligation on Great Basin Scientific, Inc. (GBSN) a molecular diagnostics company that commercializes breakthrough chip-based technologies.
The Company recently announced FDA clearance of one of its products. It has received clearance for its Bordetella Direct Test for Pertussis following a 510(k) submission on February 1, 2017. Clearance from FDA was received on Friday, March 31, approximately 57 days from submission. The Bordetella Direct Test expands Great Basin's menu of FDA cleared assays to five.
The Centers for Disease Control and Prevention (CDC) estimates that globally there are approximately 16 million cases of pertussis per year, with the disease being responsible for 195,000 deaths annually. Reported cases of pertussis in the U.S. have spiked since 1955, likely a result of declines in vaccine use, waning vaccine-induced immunity in adolescent and adult populations, and continued circulation of B. pertussis in the population.
During March 2017, the company also announced financial results for Fourth Quarter & full year ended 2016. Fourth quarter revenue increased 39% year-over-year; 2016 revenues increased 42%. Gross margin improved 42 basis points in the fourth quarter compared with third quarter of 2016, marking the greatest improvement in gross margin during 2016. The company expects to recognize revenue growth from six commercially-available assays beginning in second half of 2017, with a continued focus on cost management efforts which would lead to lower cash burn and improved gross and operating margins.
DISCLOSURE
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles, and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated, directly or indirectly, for producing or publishing this document.
http://finance.yahoo.com/news/great-basin-wha...00433.html
NEW YORK, NY / ACCESSWIRE / April 7, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is issuing a comprehensive report with no obligation on Great Basin Scientific, Inc. (GBSN) a molecular diagnostics company that commercializes breakthrough chip-based technologies.
The Company recently announced FDA clearance of one of its products. It has received clearance for its Bordetella Direct Test for Pertussis following a 510(k) submission on February 1, 2017. Clearance from FDA was received on Friday, March 31, approximately 57 days from submission. The Bordetella Direct Test expands Great Basin's menu of FDA cleared assays to five.
The Centers for Disease Control and Prevention (CDC) estimates that globally there are approximately 16 million cases of pertussis per year, with the disease being responsible for 195,000 deaths annually. Reported cases of pertussis in the U.S. have spiked since 1955, likely a result of declines in vaccine use, waning vaccine-induced immunity in adolescent and adult populations, and continued circulation of B. pertussis in the population.
During March 2017, the company also announced financial results for Fourth Quarter & full year ended 2016. Fourth quarter revenue increased 39% year-over-year; 2016 revenues increased 42%. Gross margin improved 42 basis points in the fourth quarter compared with third quarter of 2016, marking the greatest improvement in gross margin during 2016. The company expects to recognize revenue growth from six commercially-available assays beginning in second half of 2017, with a continued focus on cost management efforts which would lead to lower cash burn and improved gross and operating margins.
DISCLOSURE
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles, and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated, directly or indirectly, for producing or publishing this document.
(1)
(0)